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Edited by Richard MaraisAbstract Recent studies have identiﬁed conserved missense
mutations in PIK3CA, the gene encoding the catalytic phospha-
tidylinositol-3-kinase subunit p110a, in a variety of human can-
cers. Further investigation demonstrated that PIK3CA
mutations lead to increased basal phosphatidylinositol-3-kinase
activity, promoting cell growth and invasion [Samuels, Y., Diaz,
L.A., Jr., Schmidt-Kittler, O., Cummins, J.M., Delong, L.,
Cheong, I., Rago, C., Huso, D.L., Lengauer, C., Kinzler,
K.W., Vogelstein, B. and Velculescu, V.E. (2005) Mutant PIK3-
CA promotes cell growth and invasion of human cancer cells.
Cancer Cell 7, 561–573]. A panel of commonly used colorectal
cancer cell lines was screened for these PIK3CA mutations. Con-
stitutive and IGF-1-stimulated phosphatidylinositol-3-kinase
activity, signal response and duration were assessed. In the as-
says used no diﬀerences distinguished cells carrying PIK3CA
mutations indicating that these mutations did not signiﬁcantly al-
ter growth factor stimulated or steady state phosphatidylinositol-
3-kinase activity in normal cell culture conditions.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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cancer; HCT 116; HT291. Introduction
Class IA phosphatidylinositol-3-kinases (PI3-K) are a family
of hetrodimeric lipid kinases that regulate many cellular pro-
cesses in response to a range of diﬀerent receptor tyrosine ki-
nases (RTKs) [1]. Autophosphorylation of activated RTKs is
recognised by PI3-K regulatory subunits, such as p85a, which
cause the recruitment of PI3-K p110 catalytic subunits to the
plasma membrane. The p110 catalytic subunits can then phos-
phorylate the PI3-K substrate, phosphatidylinositol(4,5)bis-
phosphate (PtdIns(4,5)P2) on the N3 position of the inositolAbbreviations: PI3-K, phosphatidylinositol-3-kinase; IGF-1, insulin-like
growth factor1; RTK, receptor tyrosine kinase; PtdIns(4,5)P2, phos-
phatidylinositol(4,5)bisphosphate; PtdIns(3,4,5)P3, phosphatidylinosi-
tol(3,4,5)triphosphate; PKB, protein kinase B; PTEN, phosphatase
and tensin homologue deleted on chromosome 10; MIN, micro-satellite
instability; CRC, colorectal cancer; S.E.M., standard error of the mean
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doi:10.1016/j.febslet.2005.07.096ring, generating PtdIns(3,4,5)P3 [2]. Proteins with pleckstrin
homology domains then bind to PtdIns(3,4,5)P3, to activate
downstream kinases such as protein kinase B (PKB)/Akt.
The ultimate eﬀects of PI3-K activation are widely reported
to be the suppression of apoptosis and promotion of cell divi-
sion and growth, suggesting that PI3-K deregulation could
potentially be oncogenic [1]. Indeed, there is strong evidence
that the PI3-K pathway is deregulated in many human malig-
nancies, including colorectal, lung and breast cancers [3]. Re-
cently, a series of speciﬁc somatic missense mutations have
been identiﬁed in PIK3CA, the gene that encodes the catalytic
PI3-K subunit p110a, in a wide range of diﬀerent malignancies
[4–7]. Further studies using gene targeting in isogenic pairs of
colorectal cancer (CRC) cell lines with either mutant or wild
type PIK3CA demonstrated that the mutations cause constitu-
tive activation of PI3-K pathways, facilitating metastasis,
inhibiting apoptosis and producing a strong growth advantage
in conditions where growth factors are limiting [8]. However, it
is not clear whether other CRC cell lines that do not contain
these PIK3CA mutations have mutations in other PI3-K path-
way components, or increased activities, which also cause con-
stitutive activation of the PIK3CA signalling pathways. Here,
we report the determination of the p110a genotype in a panel
of eight commonly studied colorectal cancer cell lines and the
investigation of the diﬀerent PI3-K pathway characteristics of
these cell lines.2. Materials and methods
2.1. Cell culture
HCT 116 cells were cultured in McCoys5A, LS174-T, DLD-1,
HT29, Caco-2 and WiDr cells in RPMI1640 and SW480 and SW620
cells in DMEM (Gibco). All media were supplemented with 10% foetal
calf serum (Biowest). Cultures were routinely checked for mycoplasma
infection and were always negative. For certain experiments media
containing serum was replaced with serum free media and the cells cul-
tured for a further 24 h prior to treatment with 50 ng ml1 (or the indi-
cated concentration in Fig. 4) of insulin-like growth factor1 (IGF-1)
(Sigma) or vehicle control for the indicated time. Where indicated,
the PI3-K inhibitor LY294002 (Calbiochem) was added to serum
starved cells at a concentration of 40 lM, 30 min before the addition
of IGF-1 and throughout the IGF-1 incubation.
2.2. Genomic DNA sequencing
Genomic DNA was extracted from cell using a DNeasy 96 tissue kit
(Qiagen) following manufacturers instructions. Exons 9 and 20 of
PIK3CA were PCR ampliﬁed and sequenced as previously described
[7] using primer sets hCT1640694-Ex9 and hCT1640694-Ex20-2.blished by Elsevier B.V. All rights reserved.
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Western blotting was carried out as previously described [9]. The fol-
lowing primary antibodies were used; rabbit-a-p110a (Santa-Cruz sc-
7174), rabbit-a-p110b (Santa-Cruz sc-602), rabbit-a-p85a (Upstate
#06-195), mouse-a-IRS-1 (Santa-Cruz sc-8038), mouse-a-PTEN (BD
#559600), rabbit-a-PKB/Akt (Cell Signaling #9272), rabbit-a-
pS473PKB/Akt (Cell Signaling #4058) and mouse-a-actin (Sigma A
4700). An additional antibody to p110a was kindly provided by Pro-
fessor Peter Downes (Dundee University, UK).
2.4. Immunoprecipitations and PI3-K assays
PI3-K complexes were immunoprecipitated from 2 mg of total cell
lysate using 10 ll of rabbit-a-IRS-1 (Upstate #06-248) and 30 ll of
protein-A beads (Amersham Biosciences) following manufacturers
instructions. The associated PI3-K activity was then determined as pre-
viously described [10].3. Results and discussion
As the vast majority of PIK3CA mutations in clinical colo-
rectal cancer are within speciﬁc regions of the helical and ki-
nase domains [7], the exons of PIK3CA that encode these
regions were sequenced. A panel of eight colorectal cancer cell
lines were examined and of these three contained mutated
PIK3CA. HCT 116 and LS174-T cells both had an A3140G
mutation in exon 20, leading to a H1047R missense mutation
in the kinase domain, while DLD-1 cells had a G1633A and a
G1645A mutation in exon 9 which, respectively, give rise to
E545K and D549N mutations in the p110a helical domain
(Fig. 1). In all cases the mutations were only present in a singleFig. 1. Sequencing of PIK3CA. Genomic DNA was extracted from HT29,
ampliﬁed by PCR. These were then directly sequenced in two repeat exper
mutant cell lines in this ﬁgure and throughout the remaining ﬁgures are in bPIK3CA allele, although it is not clear whether the two muta-
tions present in DLD-1 cells are in the same allele. None of the
other cell lines examined (HT29, Caco-2, WiDr, SW480 and
SW620), contained mutations in these two exons (Fig. 1 and
data not shown). These data are consistent with those previously
reported that HCT 116 and DLD-1 cells contain mutations in
the kinase domain and helical domain of PIK3CA, respectively
[8]. Interestingly, the cell lines which contain mutated PIK3CA
all exhibit micro-satellite instability (MIN), while those with
wild-type PIK3CA all exhibit chromosome instability. This is
perhaps to be expected, as errors in mismatch repair presum-
ably must have occurred for the mutations in PIK3CA to have
arisen. However, it may be of interest to determine how com-
mon PIK3CA mutations are in MIN colorectal tumours, as
PIK3CA mutations may represent an important step in MIN
colorectal tumorigenesis [11].
Previous reports have shown that the PIK3CA mutations we
detected in HCT 116, LS174-T and DLD-1 cells lead to an in-
crease in PI3-K activity and constitutive activation of PI3-K
signalling pathways [7,8,12,13]. To conﬁrm this, and to deter-
mine whether CRC cell lines with wild-type PIK3CA act diﬀer-
ently, we examined the PI3-K signalling pathway
characteristics in our panel of CRC cell lines. In the ﬁrst in-
stance, we checked whether there was any correlation between
the presence of PIK3CA mutations and the levels of key PI3-K
pathway components (Fig. 2A). While there is some variation
across the panel with regards to the levels of the PI3-K cata-
lytic subunits p110a and p110b and the PI3-K regulatory sub-
unit p85a, there is no clear distinction between cell lines withHCT 116, LS174-T and DLD-1 cells and exons 9 and 20 of PIK3CA
iments with independent genomic DNA extraction. The names of the
old.
Fig. 2. Phosphatidylinositol-3-kinase activity. (A) Whole cell lysates (WCL) were assayed for the expression level of p110a, p110b, p85a and PTEN by
Western blotting. Actin is used as a protein loading control. (B) and (C) Cells were serum starved for 24 h and left untreated or treated with the PI3-K
inhibitor LY294002 (40 lM) for 30 min. The cells were then stimulated with 50 ng ml1 of IGF-1 (with or without LY294002) or vehicle control for
15 min. The level of total PKB/Akt and PKB/Akt phosphorylated on serine 473 (pS473PKB) was assayed by Western blotting. (D) Cell lines were
serum starved and treated with IGF-1 for 15 min as above. IRS-1 was immunoprecipitated and the immunoprecipitate was analysed for the level of
IRS-1, p110a and p85a by Western blotting and WCL was analysed for levels of IRS-1. The level of p85a relative to WiDr was measured by
densitometry from two independent experiments ± S.E.M. (standard error of the mean). (E) The level of PI3-K activity associated with the
immunoprecipitates from (C) was determined using an in vitro radiometric PI3-K assay. The kinase activity was normalised relative to WiDr and the
graph represents two independent experiments carried out in duplicate ± S.E.M. (F) The relative level of PI3-K activity was normalised to the relative
level of p85a present in the immunoprecipitate. All data shown are representative blots from at least two independent experiments.
C.J. Morrow et al. / FEBS Letters 579 (2005) 5123–5128 5125PIK3CA mutations compared to those with wild-type PIK3-
CA. The levels of the PtdIns(3,4,5)P3 phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) vary greatlybetween the cell lines, for example HT29 and SW620 cells have
relatively high levels while DLD-1, Caco-2 and SW480 have
low levels of PTEN. However, while this should be taken into
Fig. 3. Dynamics of the phosphatidylinositol-3-kinase pathways. (A)
LS174-T, DLD-1, HT29 and WiDr cells were serum starved for 24 h
and treated with IGF-1 for the indicated length of time. The level of
PKB/Akt and pS473PKB/Akt was assayed by Western blotting. (B)
LS174-T, DLD-1, HT29 and WiDr cells were serum starved for 24 h,
treated with IGF-1 for 15 min and then returned to serum free media
for the indicated time. The level of PKB/Akt and pS473PKB/Akt was
assayed by Western blotting. Results shown are representative of at
least three independent experiments.
5126 C.J. Morrow et al. / FEBS Letters 579 (2005) 5123–5128account when analysing later results, there is no correlation be-
tween PTEN level and PIK3CA mutations.
The next aim was to determine which, if any, of the cell lines
had: (i) constitutively active PI3-K activity, based on
LY294002 inhibitable PKB/Akt phosphorylation, and (ii) in-
creased IGF-1-stimulated PI3-K activity. To achieve this,
CRC cells were grown in the absence of serum for 24 h then
treated (or not) with IGF-1 for 15 min to stimulate PI3-K
pathways, and the level of PKB/Akt phosphorylation deter-
mined (Fig. 2B). In the absence of IGF-1, none of the cell lines
contained detectable levels of phosphorylated PKB/Akt, sug-
gesting that the PIK3CA mutations do not cause constitutive,
agonist-independent activation of PI3-K pathways in CRC cell
lines. This is in contrast to the recent report that HCT 116 and
DLD-1 cells have constitutively phosphorylated PKB/Akt
after serum starvation [8], although the length of serum starva-
tion is considerably longer in the study presented here and the
passage number of the cells used may alter these characteris-
tics. After IGF-1 stimulation there were variable levels of
PKB/Akt phosphorylation between the cell lines, for instance
LS174-T and HT29 showed high levels of PKB/Akt phosphor-
ylation while DLD-1 and Caco-2 cells showed much lower lev-
els (Fig. 2B). However, the cell lines containing high levels of
phosphorylated PKB/Akt after a 15 min IGF-1 stimulation
were not necessarily those with mutated PIK3CA. In every
case PKB/Akt phosphorylation was abolished by LY294002
treatment (Fig. 2C and data not shown), consistent with the
phosphorylation of PKB/Akt requiring PI3-K activity. Thus,
no correlation between the amount of PI3-K pathway activity
and the PIK3CA mutations in CRC cell lines could be ascer-
tained over 15 min. Similarly, in experiments where the impact
of IGF-1 on the phosphorylation status of PKB/Akt was
examined over extended times (of up to 2h) there was no cor-
relation with PIK3CA mutation status (data not shown).
One caveat to the above experiment is that phosphorylated
PKB/Akt is an indirect measure of PI3-K activity. Therefore,
while this assay is a robust measure of whether the PI3-K path-
ways are active or not, it may not accurately represent PI3-K
activity per se. To overcome this we directly measured the
PI3-K activity of each cell line after stimulation with IGF-1
using a radiometric PI3-K assay. To ensure that only PI3-K
subunits localised to the membrane, and therefore able to
phosphorylate PtdIns(4,5)P2 in the cell, were considered, the
insulin/IGF receptor intermediate IRS-1 (to which p85 binds
after IGF-1 treatment) was immunoprecipitated. The total cel-
lular level of IRS-1 and the amount that was immunoprecipi-
tated diﬀered greatly between cell lines (Fig. 2D – top two
panels). However, the amount of IRS-1 immunoprecipitated
correlated with the amount of co-immunoprecipitated p110a
and p85a in each cell line (Fig. 2D – lower two panels). The
level of PI3-K activity associated with IRS-1 diﬀered greatly
between the cell lines (Fig. 2E), although the ratio of norma-
lised kinase activity to normalised level of p85a (Fig. 2D,
graph) did not distinguish between cell lines with mutant ver-
sus wild-type PIK3CA (Fig. 2F). This suggests that the muta-
tions in PIK3CA do not cause an increase in PI3-K activity
relative to wild-type PIK3CA.
Other eﬀects of the mutations in PIK3CA could be to alter
the dynamics of PI3-K activation/deactivation following addi-
tion/removal of a PI3-K activating signal. For example, if neg-
ative inhibition of PI3-K was not very eﬀective when PIK3CA
was mutated, one would expect the PI3-K pathway to remainactive for longer following removal of this signal, which would
lead to a net increase in total PI3-K activity. We compared two
PIK3CA mutant cell lines (LS174-T and DLD-1) with two
wild-type PIK3CA cell lines (HT29 and WiDr) that had
broadly similar normalised PI3-K activities (based on
Fig. 2F). To address the issue of PI3-K activation dynamics
the four cell lines were stimulated for varying lengths of time
with IGF-1 and the level of phosphorylated PKB/Akt deter-
mined (Fig. 3A). In LS174-T (mutant, mt), HT29 (wild-type,
wt) and WiDr (wt) cells, stimulation with IGF-1 gave rise to
an increase in the phosphorylation of PKB/Akt after 1 min,
Fig. 4. Sensitivity of the phosphatidylinositol-3-kinase pathways.
LS174-T, DLD-1, HT29 and WiDr cells were serum starved for 24 h
and treated with the indicated concentration of IGF-1 for (A) 5 min or
(B) 60 min. The level of PKB/Akt and pS473PKB/Akt was assayed by
Western blotting. Results shown are representative of two independent
experiments.
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course showed that maximal PKB/Akt phosphorylation was
not seen in WiDr cells until 30 min after IGF-1 treatment –
data not shown). DLD-1 (mt) cells, on the other hand, took
over 5 min to reach a peak level of PKB/Akt phosphorylation
in a 15 min time course, while longer time courses showed that
maximal PKB/Akt phosphorylation took over 60 min to occur
(data not shown). This suggests that PKB/Akt phosphoryla-
tion in response to IGF-1 stimulation was impaired in DLD-
1 cells and raises the possibility that the mutations in the
helical domain of p110a present in DLD-1 cells may lead to
a reduced rate of PI3-K activation. Clearly, further studies
of cell lines with mutations in the helical domain of PIK3CA
would be needed to test this hypothesis.
A similar experiment was carried out to assess the dynamics
of PI3-K inactivation, where by LS174-T (mt), DLD-1(mt),
HT29 (wt) and WiDr (wt) cells were stimulated with IGF-1
for 15 min followed by culture in the absence of IGF-1 for
varying lengths of time (Fig. 3B). Once again, LS147-T (mt),
HT29 (wt) and WiDr (wt) cells behaved similarly to one an-
other, with the level of phosphorylated PKB/Akt dropping sig-
niﬁcantly within 30 min of the maximal phosphorylation
(0 min for LS174-T and HT29 and 30 min for WiDr cells)
and continuing to fall throughout the experiment. However,
the levels of PKB/Akt phosphorylation in DLD-1 cells climbed
after removal of IGF-1, consistent with maximal phosphoryla-
tion not occurring until over 60 min after IGF-1 stimulation in
DLD-1 cells, and then only fell slowly during the rest of the
experiment. However, DLD-1 cells have a relatively low level
of PTEN and therefore are less able to remove PtdIns(3,4,5)P3
from the cell than the other three cell lines, implying that they
would be less able to inhibit PI3-K signalling. Indeed, Caco-2
cells, which also contain a low level of PTEN (Fig. 2A), exhibit
a similar slow rate of loss of phosphorylated PKB/Akt (data
not shown). Therefore, while the mutation in the helical do-
main of p110a present in DLD-1 cells may impair negative
inhibition of PI3-K pathways, it seems more likely that this
is due to reduced PTEN activity.
The ﬁnal potential consequence of PIK3CA mutations that
we examined was an alteration in the sensitivity of cells to
growth factor stimulation. If, for instance, PIK3CA mutations
allowed the cell to respond to reduced levels of growth factors,
they would impart a considerable growth advantage to cells
containing PIK3CA mutations during tumorigenesis, when
growth factors are often limited. LS174-T (mt), DLD-1(mt),
HT29 (wt) and WiDr (wt) cells were serum starved, stimulated
for 5 or 60 min with varying concentrations of IGF-1 and the
level of phosphorylated PKB/Akt determined by Western blot-
ting (Figs. 4A and B). In all the cell lines studied, increased
concentrations of IGF-1 lead to increased levels of phosphor-
ylated PKB/Akt. In the case of LS174-T (mt), HT29 (wt) and
WiDr (wt) cells, concentrations of IGF-1 of 25 ng ml1and
above elicit a strong phospho-PKB/Akt response after both 5
and 60 min. DLD-1 (mt) cells, however, contained readily
detectable levels of phosphorylated PKB/Akt at much lower
concentrations of IGF-1, especially after 60 min of stimula-
tion. This could imply that the mutations present in the helical
domain of p110a in DLD-1 cells leads to an increased sensitiv-
ity to growth factor stimulation, although it seems more likely
to be explained by the low levels of PTEN in DLD-1 cells.
Therefore, it is does not appear that the mutations in PIK3CA
cause increased sensitivity to growth factor stimulation.In summary, this study has shown that the mutations de-
tected in the helical and kinase domains of PIK3CA do not
seem to aﬀect the PI3-K pathway characteristics of the eight
cell lines studied in any of the assays performed. This is sur-
prising, as previous studies have shown that PIK3CA muta-
tions lead to constitutive activation of PI3-K signalling in
HCT 116 and DLD-1 backgrounds [8] and that mutated
p110a has a higher kinase activity relative to wild-type
p110a [7,12,13]. It is possible that the assays used here are
not sensitive enough to detect a low level of constitutive PI3-
K activation. However, there is clearly a marked increase after
induction with IGF-1 over any basal constitutive levels of PI3-
K signalling in all the cell lines studied, regardless of the PIK3-
CA status of the cell line (Figs. 2B, C and 3A). Furthermore,
5128 C.J. Morrow et al. / FEBS Letters 579 (2005) 5123–5128we demonstrate that the reported increased basal PI3-K activ-
ity associated with exogenous, over expressed mutant PIK3CA
(compared to exogenous over expressed wild type PIK3CA)
[7,12,13] is not mirrored when endogenous PI3-K activity asso-
ciated with IRS-1 after induction with IGF-1 is compared be-
tween cells with mutant or wild-type endogenous PIK3CA
(Figs. 2E and F). Thus, in the panel of routinely used colorec-
tal cell lines, (three with mutation in PIK3CA and ﬁve with-
out), we have not been able to identify diﬀerences in basal or
induced PI3-K activity, suggesting the possibility that other
pathway aberrations may mimic the impact of mutant PIK3-
CA.
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